The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Belousov Iu.B.

GBOU VPO "Rossiĭskiĭ natsional'nyĭ issledovatel'skiĭ meditsinskiĭ universitet im. N.I. Pirogova" Minzdrava Rossii, Moskva

Danilov A.N.

Kafedra klinicheskoĭ farmakologii RGMU, Moskva

Zyrianov S.K.

Kafedra klinicheskoĭ farmakologii LF Rossiĭskogo natsional'nogo issledovatel'skogo meditsinskogo universiteta im. N.I. Pirogova

Rational pharmaco-therapeutic algorithms for the management of Alzheimer's disease

Authors:

Belousov Iu.B., Danilov A.N., Zyrianov S.K.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(7): 59‑64

Read: 1164 times

Download PDF (RU)
Contact the author
Table of contents

RATIONAL PHARMACO-THERAPEUTIC ALGORITHMS FOR THE MANAGEMENT OF ALZHEIMER'S DISEASE
RATIONAL PHARMACO-THERAPEUTIC ALGORITHMS FOR THE MANAGEMENT OF ALZHEIMER'S DISEASE

To cite this article:

Belousov IuB, Danilov AN, Zyrianov SK. Rational pharmaco-therapeutic algorithms for the management of Alzheimer's disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(7):59‑64. (In Russ.)

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Neurobiological pote­ntial of astragaloside IV and prospects for its use in the treatment of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):7-12
Combined treatment of patients with acute muscular tonic syndrome with dorsopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):70-77
Stress and sleep: Neurobiological aspe­cts and modern options of inso­mnia therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):14-21
Cyto­kine status of patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):5-12
Curcumin-induced increased reti­nal fluorescence as a new method in the early diagnosis of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):19-25
Differential diagnosis of Alzheimer’s disease and vascular cognitive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):26-35
A comprehensive study of Alzheimer’s disease biomarkers in plasma and cere­brospinal fluid. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):43-53
Characteristics, treatment features and in-hospital mortality of patients with myocardial infa­rction over 75 years old in Russia acco­rding to the REGION-IM regi­stry. Russian Cardiology Bulletin. 2025;(1):22-38
Pharmacological treatment and prevention of ischemia-reperfusion syndrome in percutaneous coro­nary inte­rvention. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):191-200
Influence of griseofulvin on inte­stinal microbiota in the treatment of microsporia in rural children. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):185-190
Abstract:

Keywords:

Alzheimer's disease
treatment
acetylholinest inhibitors
NMDA-receptors

Authors:

Belousov Iu.B.

GBOU VPO "Rossiĭskiĭ natsional'nyĭ issledovatel'skiĭ meditsinskiĭ universitet im. N.I. Pirogova" Minzdrava Rossii, Moskva

Danilov A.N.

Kafedra klinicheskoĭ farmakologii RGMU, Moskva

Zyrianov S.K.

Kafedra klinicheskoĭ farmakologii LF Rossiĭskogo natsional'nogo issledovatel'skogo meditsinskogo universiteta im. N.I. Pirogova

Close metadata

References:

  1. Belousov Yu.B. Transdermal'nye terapevticheskie sistemy. Kachestvennaya klinicheskaya praktika 2001;1:7-10.
  2. Ballard G.G. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur Neurol 2002;47:64-70.
  3. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006;CD005593.
  4. Dantoine T., Auriacombe S., Sarazin M. et al. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment. Int J Clin Pract 2006;60:1:110-118.
  5. Farlow M., Anand R., Messina J. Jr. et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 2000;44:4:236-241.
  6. Farlow M.R., Cummings J.L. Effective pharmacologic management of Alzheimer disease. Am J Med 2007;120:388-397.
  7. Final report is now available. IQWiG doubts the effectiveness of memantine. MMW Fortschr Med 2009;151:39:6.
  8. Francis P.T., Palmer A.M., Snape M. et al. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiat 1999;66:137-147.
  9. Gehrman P.R., Connor D.J., Martin J.L. et al. Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease. Am J Geriat Psychiat 2009;17:2:166-169.
  10. Gill S.S., Anderson G.M., Fischer H.D. et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Int Med 2009;169:9:867-873.
  11. Haag M.D., Hofman A., Koudstaal P.J. et al. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiat 2009;80:1:13-17.
  12. Horsdal H.T., Olesen A.V., Gasse C. et al. Use of statins and risk of hospitalization with dementia: a Danish population-based case-control study. Alzheimer Dis Ass Dis 2009;23:1:18-22.
  13. Hynd M.R., Scott H.L., Dodd P.R. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int 2004;45:5:583-595.
  14. Imbimbo B.P. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. CNS Drugs 2001;15:5:375-390.
  15. McGeer P.L., McGeer E.G. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging 2007;28:5:639-647.
  16. Petersen R.C., Thomas R.G., Grundman M. et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:23:2379-2388.
  17. Porsteinsson A.P., Grossberg G.T., Mintzer J. et al. Memantine treatment in patients with mild to moderate Alzheimers disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008;5:1:83-89.
  18. Raskind M.A., Peskind E.R., Wessel T., Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000;54:12:2261-2268.
  19. Rogers S.L., Farlow M.R., Doody R.S. et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998;50:1:136-145.
  20. Rosler M., Anand R., Cicin-Sain A. et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999;318:7184:633-638.
  21. Schmitt F.A., van Dyck C.H., Wichems C.H. et al. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Dis Ass Dis 2006;20:4:255-262.
  22. Schneider L.S., Anand R., Farlow M.R. Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease. Int J Geriatr Psychopharmac 1998;1:Suppl 1:26-34.
  23. Simpkins J.W., Singh M. More than a decade of estrogen neuroprotection. Alzheimers Dement 2008;4:1:Suppl 1:131-136.
  24. Waldemar G., Dubois B., Emre M. et al. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 2007;14:1-26.
  25. Winblad B., Jelic V. Long-term treatment of Alzheimer disease: efficacy and safety for acetylholinesterase inhibitors. Alzheimer Dis Ass Dis 2004;18:Suppl 1:2-8.
  26. Winblad B., Grossberg G., Frölich L. et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007;69:4:Suppl 1:14-22.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.